BamSEC and AlphaSense Join Forces
Learn More

Coherus Oncology Inc.

NASDAQ: CHRS    
Share price (8/14/25): $1.02    
Market cap (8/14/25): $119 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 10-Q 15 pages Coherus Oncology, Inc. Executive Change in Control and Severance Plan (And Summary Plan Description) Effective January 1, 2023
12/34/56
EX-10.5
from 10-Q 29 pages Coherus Oncology, Inc. 2016 Employment Commencement Incentive Plan Article 1. Purpose
12/34/56
EX-10.4
from 10-Q 1 page ​ Amendment No. 1 to Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan
12/34/56
EX-10.3
from 10-Q 10 pages Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan
12/34/56
EX-10.2
from 10-Q 29 pages Article 2. Definitions and Construction
12/34/56
EX-10.1
from 10-Q 8 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.5
from 10-Q 39 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.4
from 10-Q 14 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.3
from 10-Q 29 pages Article 2. Definitions and Construction
12/34/56
EX-10.2
from 8-K/A 64 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance. ​
12/34/56
EX-10.1
from 8-K/A 109 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 3 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance. Amendment No. 2 to Exclusive License and Commercialization Agreement
12/34/56
EX-10.40
from 10-K 25 pages Exclusive Product License Agreement
12/34/56
EX-10
from 10-K 5 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 4 pages Coherus Biosciences, Inc. ​ Common Stock Amendment No. 2 to Sales Agreement
12/34/56
EX-10.1
from 10-Q 21 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.1
from 10-Q 3 pages Coherus Biosciences, Inc. ​ Common Stock Amendment No. 1 to Sales Agreement
12/34/56
EX-10.3
from 10-Q 6 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 15 pages Coherus Biosciences, Inc. Executive Change in Control and Severance Plan (And Summary Plan Description) Effective January 1, 2023
12/34/56
EX-10.1
from 10-Q 26 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56